Abstract
BackgroundInnate and acquired resistance are major concerns that limit the patient’s response to immune checkpoint therapy.1 Immune-boosting gene therapies have been shown to improve response in models of checkpoint blockade...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
